{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T10:02:12Z","timestamp":1780048932133,"version":"3.53.1"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,29]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Case series have indicated that intravenous antibiotics may be effective in severe hidradenitis suppurativa (HS) treatment. This treatment approach is excluded from the British Association of Dermatologists UK HS treatment guidelines but can be found in the European S2k, North American and French Dermatology Society HS guidelines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To study whether intravenous antibiotics are being used in HS treatment in the UK and to explore the experiences of dermatologists and outpatient parenteral antibiotic therapy (OPAT) teams with intravenous antibiotics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Two separate surveys were distributed to dermatologists and OPAT centres respectively in 2020. The surveys were designed on Survey Monkey\u00ae with skip logic and free text boxes incorporated. Only UK responses were included. Descriptive and content analyses were performed on the data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Seventy-four dermatology clinicians and 25 OPAT centres responded. Nearly half of the respondents reported having treated HS with intravenous antibiotics. Most used intravenous ertapenem for an average treatment duration of 4\u20136 weeks with 1\u20133 months of average remission period. Top indications were severe disease (57%) and biologic treatment failure (57%). The most common consolidation treatments were biologics, surgery and tetracycline antibiotics. A joint dermatology\u2013OPAT HS clinic was preferred. Dermatologists reported exclusion of intravenous antibiotics from local\/national guidelines (67%) being the main barrier to using intravenous antibiotics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Findings from the two surveys show overall positive experience using intravenous antibiotics in HS treatment and call for development of a best practice statement in HS treatment with intravenous antibiotics and collaborative working with OPAT for a national referral pathway.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/skinhd\/vzag005","type":"journal-article","created":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T12:38:11Z","timestamp":1769171891000},"page":"291-297","source":"Crossref","is-referenced-by-count":0,"title":["A survey of UK-based dermatologists and Outpatient Parenteral Antimicrobial Therapy centres to evaluate the use of intravenous antibiotics as a treatment for hidradenitis suppurativa"],"prefix":"10.1093","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7971-3227","authenticated-orcid":false,"given":"Mun Wai","family":"Lam","sequence":"first","affiliation":[{"name":"Department of Dermatology, University Hospitals of Leicester NHS Trust, Leicester Royal Infirmary, Infirmary Square , Leicester ,","place":["UK"]},{"name":"Department of Dermatology, Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust , Birmingham ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9328-2398","authenticated-orcid":false,"given":"Ryan A","family":"Hamilton","sequence":"additional","affiliation":[{"name":"School of Pharmacy, De Montfort University , Leicester ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena A","family":"White","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, University Hospitals of Leicester NHS Trust , Leicester ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen E","family":"Harman","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospitals of Leicester NHS Trust, Leicester Royal Infirmary, Infirmary Square , Leicester ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,3,13]]},"reference":[{"key":"2026052905165545700_vzag005-B1","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/jdv.12966","article-title":"European S1 guideline for the treatment of hidradenitis suppurativa\/acne inversa","volume":"29","author":"Zouboulis","year":"2015","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"2026052905165545700_vzag005-B2","first-page":"15","volume-title":"Fitzpatrick\u2019s Color Atlas and Synopsis of Clinical Dermatology","author":"Wolff","year":"2017","edition":"8th edn"},{"key":"2026052905165545700_vzag005-B3","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1046\/j.1365-2133.2000.03476.x","article-title":"The clinical genetics of hidradenitis suppurativa revisited","volume":"142","author":"Von Der Werth","year":"2000","journal-title":"Br J Dermatol"},{"key":"2026052905165545700_vzag005-B4","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1016\/j.jid.2020.02.046","article-title":"The surface microbiome of clinically unaffected skinfolds in hidradenitis suppurativa: a cross-sectional culture-based and 16S rRNA gene amplicon sequencing study in 60 patients","volume":"140","author":"Riverain-Gillet","year":"2020","journal-title":"J Invest Dermatol"},{"key":"2026052905165545700_vzag005-B5","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1001\/jamadermatol.2017.0904","article-title":"The follicular skin microbiome in patients with hidradenitis suppurativa and healthy controls","volume":"153","author":"Ring","year":"2017","journal-title":"JAMA Dermatol"},{"key":"2026052905165545700_vzag005-B6","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.jid.2019.08.445","article-title":"Skin microbiota perturbations are distinct and disease severity-dependent in hidradenitis suppurativa","volume":"140","author":"Naik","year":"2020","journal-title":"J Invest Dermatol"},{"key":"2026052905165545700_vzag005-B7","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3390\/vaccines11010179","article-title":"Consistency of bacterial triggers in the pathogenesis of hidradenitis suppurativa","volume":"11","author":"Rosi","year":"2023","journal-title":"Vaccines (Basel)"},{"key":"2026052905165545700_vzag005-B8","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1111\/bjd.17537","article-title":"British Association of Dermatologists guidelines for the management of hidradenitis suppurativa (acne inversa) 2018","volume":"180","author":"Ingram","year":"2019","journal-title":"Br J Dermatol"},{"key":"2026052905165545700_vzag005-B9","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/ajd.12075","article-title":"Non-antibiotic properties of tetracyclines and their clinical application in dermatology","volume":"55","author":"Perret","year":"2014","journal-title":"Australas J Dermatol"},{"key":"2026052905165545700_vzag005-B10","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1159\/000228337","article-title":"The effect of combined treatment with oral clindamycin and oral rifampicin in patients with hidradenitis suppurativa","volume":"219","author":"van der Zee","year":"2009","journal-title":"Dermatology"},{"key":"2026052905165545700_vzag005-B11","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s00403-013-1409-7","article-title":"Dapsone in dermatology and beyond","volume":"306","author":"Wozel","year":"2014","journal-title":"Arch Dermatol Res"},{"key":"2026052905165545700_vzag005-B12","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1111\/ced.14512","article-title":"Long-term antibiotic use for the treatment of hidradenitis suppurativa consistent with guideline recommendations","volume":"46","author":"Kitts","year":"2021","journal-title":"Clin Exp Dermatol"},{"key":"2026052905165545700_vzag005-B13","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1093\/ced\/llaf160","article-title":"Is there still a role for clindamycin and rifampicin in the treatment of hidradenitis suppurativa? A review of the literature","volume":"50","author":"Wainman","year":"2025","journal-title":"Clin Exp Dermatol"},{"key":"2026052905165545700_vzag005-B14","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1093\/jac\/dkv361","article-title":"Efficacy of ertapenem in severe hidradenitis suppurativa: a pilot study in a cohort of 30 consecutive patients","volume":"71","author":"Join-Lambert","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"2026052905165545700_vzag005-B15"},{"key":"2026052905165545700_vzag005-B16","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1365-2648.2007.04569.x","article-title":"The qualitative content analysis process","volume":"62","author":"Elo","year":"2008","journal-title":"J Adv Nurs"},{"key":"2026052905165545700_vzag005-B17"},{"key":"2026052905165545700_vzag005-B18","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jaad.2019.02.068","article-title":"North American clinical management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian Hidradenitis Suppurativa Foundations. Part II: topical, intralesional and systemic medical management","volume":"81","author":"Alikhan","year":"2019","journal-title":"J AmAcad Dermatol"},{"key":"2026052905165545700_vzag005-B19","doi-asserted-by":"crossref","first-page":"dlz026","DOI":"10.1093\/jacamr\/dlz026","article-title":"Updated good practice recommendations for outpatient parenteral antimicrobial therapy (OPAT) in adults and children in the UK","volume":"1","author":"Chapman","year":"2019","journal-title":"JAC Antimicrob Resist"},{"key":"2026052905165545700_vzag005-B20","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.12968\/bjon.2021.30.2.S4","article-title":"Maximising the opportunity of a self-administration outpatient parenteral antimicrobial therapy pathway","volume":"30","author":"Bodycot","year":"2021","journal-title":"Br J Nurs"},{"key":"2026052905165545700_vzag005-B21","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1111\/ijd.14036","article-title":"Ertapenem\u2014a potent treatment for clinical and quality of life improvement in patients with hidradenitis suppurativa","volume":"57","author":"Braunberger","year":"2018","journal-title":"Int J Dermatol"},{"key":"2026052905165545700_vzag005-B22","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1111\/bjd.19710","article-title":"Guidelines for the management of hidradenitis suppurativa: recommendations supported by the Centre of Evidence of the French Society of Dermatology","volume":"184","author":"Bertolotti","year":"2021","journal-title":"Br J Dermatol"},{"key":"2026052905165545700_vzag005-B23","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1111\/bjd.15739","article-title":"Oral ofloxacin and clindamycin as an alternative to the classic rifampicin-clindamycin in hidradenitis suppurativa: retrospective analysis of 65 patients","volume":"178","author":"Delaunay","year":"2018","journal-title":"Br J Dermatol"},{"key":"2026052905165545700_vzag005-B24","doi-asserted-by":"crossref","first-page":"S66","DOI":"10.1016\/j.jid.2020.03.497","article-title":"Intravenous ertapenem therapy for advanced hidradenitis suppurativa","volume":"140","author":"Babbush","year":"2020","journal-title":"J Invest Dermatol"},{"key":"2026052905165545700_vzag005-B25","doi-asserted-by":"crossref","first-page":"S110","DOI":"10.1093\/ofid\/ofx163.115","article-title":"More than just an anti-infective agent: a prospective pilot clinical trial to determine the effectiveness of IV ertapenem in severe hidradenitis suppurativa","volume":"4","author":"Ramesh","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"2026052905165545700_vzag005-B26","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1111\/jdv.20472","article-title":"European S2k guidelines for hidradenitis suppurativa\/acne inversa part 2: treatment","volume":"39","author":"Zouboulis","year":"2025","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026052905165545700_vzag005-B27","author":"Cabinet Office"},{"key":"2026052905165545700_vzag005-B28","author":"NHS England"},{"key":"2026052905165545700_vzag005-B29","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.diagmicrobio.2018.07.013","article-title":"Outpatient parenteral antimicrobial therapy (OPAT) in the UK: a cross-sectional survey of acute hospital trusts and health boards","volume":"93","author":"Durojaiye","year":"2019","journal-title":"Diagn Microbiol Infect Dis"}],"container-title":["Skin Health and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/skinhd\/article-pdf\/6\/3\/291\/67341514\/vzag005.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/skinhd\/article-pdf\/6\/3\/291\/67341514\/vzag005.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T09:17:07Z","timestamp":1780046227000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/skinhd\/article\/6\/3\/291\/8519526"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,13]]},"references-count":29,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3,13]]},"published-print":{"date-parts":[[2026,5,29]]}},"URL":"https:\/\/doi.org\/10.1093\/skinhd\/vzag005","relation":{},"ISSN":["2690-442X"],"issn-type":[{"value":"2690-442X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2026,3,13]]}}}